The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.
DC News Now on MSN
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The FDA expanded the approval of Moderna’s RSV vaccine to include people 18 to 59 years old who are at increased risk for ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
WASHINGTON -- Moderna is applying for full government approval for its COVID-19 vaccine. The company said it is submitting trial data to the Food and Drug Administration on a rolling basis over the ...
Moderna says the Food and Drug Administration has issued full approval for its COVID-19 vaccine for use in people aged 18 and older. The company made the announcement in a press release on Monday ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results